Date: 2016-11-15
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the Annual Meeting of the American Society of Hematology
Company: Immunomedics (USA - NJ)
Product: IMMU-140
Action
mechanism: antibody drug conjugate/ADC.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On November 15, 2016, Immunomedics announced that the company has created IMMU-140, the subject of U.S. Patent 9,493,573 issued for additional claims under the patent family, “Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity.”
The parent antibody in IMMU-140 is an anti-HLA-DR IgG4 antibody (IMMU-114) that has demonstrated evidence of treatment responses in more than 50% of assessable patients in a Phase 1 study in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) without reaching a maximum tolerated dose. At the Annual Meeting of the American Society of Hematology, to be held December 3-6, 2016, the Company will present preclinical results on in vitro and in vivo activity of IMMU-140 in animal models of five liquid cancers, NHL, CLL, acute myelocytic and lymphocytic leukemia, and multiple myeloma.
The Company has also created yet another ADC targeting B-cell hematologic malignancies. Protected by the new U.S. Patent 9,493,574 under the same patent family of “Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity,” this new ADC comprises a humanized anti-CD19 antibody, hA19, conjugated to SN-38. These new ADC patents will expire in July 2033.
